AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q90288

U.S. Application No.: 10/549,902

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

**LISTING OF CLAIMS:** 

1. (currently amended): A method of treatment of a human or non-human animal

subject to combat inflammation arising from a condition associated with or without pain wherein

the inflammation is sub-dermal and in soft tissue, said method comprising administering to said

subject an effective amount of a physiologically tolerable strontium compound,

wherein said strontium compound is administered to the surface of the skin.

2. (canceled).

3. (previously presented): The method as claimed in claim 1, wherein said

inflammation is not associated with pain.

4. (previously presented): The method as claimed in claim 1, wherein said

inflammation is not associated with a sporting injury.

5. (previously presented): The method as claimed in claim 1, wherein said

administration is not oral.

6-7. (canceled).

8. (previously presented): The method as claimed in claim 1, wherein said strontium

compound is administered further with a skin penetration enhancing agent.

9. (previously presented): The method as claimed in claim 8, wherein said skin

penetration enhancing agent is dimethylsulphoxide.

2

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Attorney Docket No.: Q90288 U.S. Application No.: 10/549,902

10. (previously presented): The method as claimed in claim 1, wherein said strontium compound is selected from the group consisting of strontium chloride, strontium acetate and strontium nitrate.

- 11. (previously presented): The method as claimed in claim 1, wherein said strontium compound is a strontium complex with a chelating agent.
- 12. (previously presented): The method as claimed in claim 11, wherein said chelating agent is present in at least 2% mol excess relative to strontium.
- 13. (previously presented): The method as claimed in claim 12, wherein said chelating agent is present in an excess of at least 50% mol relative to strontium.
- 14. (previously presented): The method as claimed in claim 1, wherein said inflammation is associated with acne vulgaris.
- 15. (previously presented): The method as claimed in claim 1, wherein said inflammation is associated with psoriasis
- 16. (previously presented): The method as claimed in claim 1, wherein said inflammation is associated with radiation therapy.
- 17. (previously presented): The method as claimed in claim 1, wherein said inflammation is associated with arthritis.
- 18. (previously presented): The method as claimed in claim 2, wherein said inflammation is not associated with pain.